Correction to: O ncogene (2010) 29, 2130–2141; doi:10.1038/onc.2009.491
Since the publication of the above article the authors have identified an error in the labelling of Figure 4c and in the listing of the siRNA sequence of BI-1 in the Materials and Methods section.
Shown here is the corrected version of Figure 4c—BI-1, and Neo labelling has been reversed.
The below paragraph from the Materials and Methods section of the paper has been amended to correct the listing of the siRNA sequence for BI-1.
siRNA transfection
The siRNAs were synthesized in duplex and purified forms using Bioneer technology (Daejon, South Korea). The double-strand small interfering RNAs (siRNAs) targeting BI-1 (for BI-1 siRNA, 5′-GUGCUAUCCUACGAAAUCA-3′ (forward) and 5′-UGAUUUCGUAGGAUAGCAC-3′ (reverse); for non-specific siRNA, 5′-CUGAACAACCAAUGCAAAU-3′ (forward) and 5′-AUUUGCAUUGGUUGUUCAG-3′ (reverse)) were transfected separately or together into Neo and BI-1 cells using Amaxa Nucleofector (Amaxa, Gaithersburg, MD, USA). Briefly, confluent cells were trypsinized and resuspended in Amaxa Nucleofector solution at 2 × 105 cells per 100 μl of solution, and BI-1 or on-specific siRNA was added. Cells were transfected by electroporation using the A24 pulsing program.
The authors wish to apologise for any inconvenience caused and confirm that the conclusions drawn from this research are not affected by this error.
Additional information
The online version of the original article can be found at 10.1038/onc.2009.491
Rights and permissions
About this article
Cite this article
Lee, GH., Yan, C., Shin, SJ. et al. Erratum: BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium-hydrogen exchanger: the alteration of mitochondrial function. Oncogene 35, 803–804 (2016). https://doi.org/10.1038/onc.2015.421
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.421